2. Search Result
Search Result
Results for "

HCC1806

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148185
    T01-1

    KL610023

    		 ADC Payload Cancer
    T01-1 is an anticancer agent (camptothecin derivative) with good anti-proliferative activity .
    T01-1
  • HY-147340
    TL033

    Tirumotecan

    		 Drug-Linker Conjugates for ADC Cancer
    TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
    TL033
  • HY-139342
    CDK7-IN-4

    		CDK Cancer
    CDK7-IN-4 (compound I) is a potent CDK7 (Cyclin-dependent kinase 7) inhibitor. CDK7-IN-4 shows anticancer activity. CDK7-IN-4 inhibits the in vitro growth of cancer cell lines from a variety of histologies including colon , breast , lung , ovary and stomach , in a dose dependent manner .
    CDK7-IN-4
  • HY-171789
    PARG-IN-7

    		Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    PARG-IN-7 (Example 38) is a Poly ADP-ribose glycohydrolase (PARG) inhibitor (IC50: < 0.1 μM). PARG-IN-7 inhibits cell viability of HCC1806-XRCC1 KD (knock down) cells with an IC50 < 1 μM. PARG-IN-7 can be used for cancer research .
    PARG-IN-7
  • HY-145389
    SZ-015268

    		CDK Cancer
    SZ-015268 is a CDK7 inhibitor with an IC50 of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC50s of 33, 80.56, 12.53, and 61.55 nM, respectively .
    SZ-015268
  • HY-158439
    anti-TNBC agent-7

    		JAK STAT Cancer
    anti-TNBC agent-7 (Compound 13c) possesses anticancer activity, serving as a molecular probe to recognize and regulate the signal transduction of the USP21/JAK2/STAT3 axis, exhibiting nanomolar-level cytotoxicity against MDA-MB-231 and HCC-1806 cancer cells, effectively combating triple-negative breast cancer (TNBC) .
    anti-TNBC agent-7
  • HY-P991328
    MAb604.107

    		Notch Cancer
    MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
    MAb604.107
  • HY-170549
    VEGFR-2-IN-60

    		VEGFR Cancer
    VEGFR-2-IN-60 (compound 5c) is a potent VEGFR-2 inhibitor with an IC50 of 1.07 nM. VEGFR-2-IN-60 exhibits cytotoxic activity against HCC1806, Hela, and A549 cell lines .
    VEGFR-2-IN-60
  • HY-149847
    JH530

    		Ras Cancer
    JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research .
    JH530
  • HY-161780
    Maleimide-PEG8-Val-Ala-PAB-SNS032

    		Drug-Linker Conjugates for ADC CDK Cancer
    Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules .
    Maleimide-PEG8-Val-Ala-PAB-SNS032
  • HY-163619
    Anticancer agent 227

    		Apoptosis Mitophagy Cancer
    Anticancer agent 227 (compound YNU-1c) is a potent anticancer agent. Anticancer agent 227 shows antiproliferative activity. Anticancer agent 227 induces apoptosis and mitophagy .
    Anticancer agent 227
  • HY-182820
    YZ-836P

    		Histone Methyltransferase PROTACs KLF Cancer
    YZ-836P is a Protein arginine methyltransferase 5 (PRMT5) targeting agent. YZ-836P promotes ubiquitination and proteasomal degradation of PRMT5 in a cereblon (CRBN)-dependent manner, which in turn reduces levels of its downstream target KLF5. YZ-836P induces G1 phase cell cycle arrest in triple-negative breast cancer cells. YZ-836P induces Apoptosis in triple-negative breast cancer cells. YZ-836P exerts cytotoxic effects on triple-negative breast cancer cells. YZ-836P inhibits the growth of triple-negative breast cancer patient-derived organoids. YZ-836P inhibits the growth of triple-negative breast cancer xenografts in nude mice. YZ-836P can be used for the research of triple-negative breast cancer .
    YZ-836P

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: